Affiliations of authors: Department of Health Sciences, University Milano Bicocca, Monza, Italy (CGP, FF, AS, SR, MC, LMo, CM, LA, RP); Hematology Unit (CGP) and Nuclear Medicine and PET Unit (CM, LG), San Gerardo Hospital, Monza, Italy; M Tettamanti Research Center, Pediatric Clinic University of Milano Bicocca, Monza, Italy (GG); Medical Genetics Laboratory, San Gerardo Hospital, Monza, Italy (ES); Istituto di Ricerca Pediatrico Fondazione Città della Speranza, Pediatric Clinic University of Padova, Padova, Italy (LMu); H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium (DD); Trillium Health Centre, Mississauga Site, Mississauga ON, Canada (MHK); Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria (MS); Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (RO); Hematology Institute, Beilinson Hospital, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (AMC); Department of Haematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany (MG); Hematology/Stem Cell Transplantation, Maisonneuve Rosemont/University of Montreal, Montreal, QC, Canada (LB); School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland (GC).
J Natl Cancer Inst. 2014 Feb;106(2):djt378. doi: 10.1093/jnci/djt378.
Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were resistant/refractory to cytotoxic therapy. The overall response rate was 10 of 11 (90.9%; 95% confidence interval [CI] = 58.7% to 99.8%). Disease status at the latest follow-up is as follows: four patients are in complete response (CR) (months >21, >30, >35, >40) under continuous crizotinib administration; 4 patients had progression of disease (months 1, 2, 2, 2); 1 patient obtained CR on crizotinib, received an allogeneic bone marrow transplant, and is in CR; 2 patients (treated before and/or after allogeneic bone marrow transplant) obtained and are still in CR but they have stopped crizotinib. Overall and progression-free survival rates at 2 years are 72.7% (95% CI = 39.1% to 94.0%) and 63.7% (95% CI = 30.8% to 89.1%), respectively. ALK mutations conferring resistance to crizotinib in vitro could be identified in relapsed patients. Crizotinib exerted a potent antitumor activity with durable responses in advanced, heavily pretreated ALK+ lymphoma patients, with a benign safety profile.
间变性淋巴瘤激酶 (ALK)-阳性淋巴瘤对化疗有反应，但会复发，预后不良。克唑替尼在体外和体内均能抑制 ALK，并对 11 例对细胞毒性治疗耐药/难治的 ALK+淋巴瘤患者进行单药治疗。总缓解率为 11 例中的 10 例（90.9%；95%置信区间[CI] = 58.7%至 99.8%）。截至最新随访时的疾病状态如下：4 例患者在持续接受克唑替尼治疗下处于完全缓解（CR）（>21、>30、>35、>40 个月）；4 例患者疾病进展（1、2、2、2 个月）；1 例患者在接受克唑替尼治疗后获得 CR，接受异基因骨髓移植，并处于 CR；2 例患者（在异基因骨髓移植之前和/或之后接受治疗）获得并仍处于 CR，但已停止使用克唑替尼。2 年时的总生存率和无进展生存率分别为 72.7%（95%CI = 39.1%至 94.0%）和 63.7%（95%CI = 30.8%至 89.1%）。在复发患者中可鉴定出体外对克唑替尼耐药的 ALK 突变。克唑替尼在晚期、预处理较多的 ALK+淋巴瘤患者中具有持久的抗肿瘤活性和持久的缓解作用，安全性良好。
